Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Spruce Biosciences, Inc.NASDAQ: SPRB
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $4.41M rose 20.7% year over year, behind the +26.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 36.9% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $77.79M (+357.8%) for the fiscal year ending Dec 2026, a step up from the +16.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.41M-36.9% QoQ
- Last fiscal yearDec 2025
- $16.99M+16.0% YoY
- LTMMar 2026
- $17.75M+26.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 16.99M USD
- Year-over-year change
- +16.0%
- 4-year CAGR
- +10.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.99M | +16.0% |
| FY2024 | 2024-12-31 | 14.64M | +15.8% |
| FY2023 | 2023-12-31 | 12.65M | +4.7% |
| FY2022 | 2022-12-31 | 12.09M | +6.3% |
| FY2021 | 2021-12-31 | 11.37M | — |
Selling, General & Admin vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 selling, general & admin of $17.75M is the 4th highest of the 9 companies compared; the peer median is $16.04M.
- Its year-over-year change of +26.9% is the 2nd highest of 9, against a peer median of +8.0%.
- Over three fiscal years its annual growth of +12.0% compares with a peer median of -4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $12.34B | +166786.7% | +2103.6% | — |
| LTM Mar 2026 | $38.12M | -1.4% | +24.4% | 11443.7% | |
| LTM Jun 2026 | $19.35M | +4.7% | -9.7% | 92.1% | |
| LTM Mar 2026 | $17.75M | +26.9% | +12.0% | — | |
| LTM Mar 2026 | $16.21M | +11.3% | +0.2% | 49.5% | |
| LTM Mar 2026 | $15.87M | +18.9% | +7.0% | 43.1% | |
| LTM Mar 2026 | $13.76M | +12.8% | -21.8% | 600.0% | |
| LTM Mar 2026 | $10.46M | -6.1% | -14.5% | — | |
| LTM Mar 2026 | $8.86M | +3.4% | -29.6% | 626.3% | |
| Peer median (excluding SPRB) | $16.04M | +8.0% | -4.8% | 346.1% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 10.09M | 4.91M | 0 |
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Research & Development | 30.7M | 35.2M | 49.43M | 46.42M | 19.52M |
| Selling, General & Admin | 11.37M | 12.09M | 12.65M | 14.64M | 16.99M |
| Operating Expenses | 42.07M | 47.28M | 62.08M | 61.06M | 36.51M |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| EBITDA | (41.88M) | (45.69M) | (47.37M) | (52.68M) | (38.86M) |
| EBITDA Margin | — | — | -469.5% | -1072.8% | — |
| Operating Income | (42.07M) | (47.28M) | (51.99M) | (56.15M) | (36.51M) |
| Operating Margin | — | — | -515.3% | -1143.4% | — |
| Interest Income | 119K | 1.52M | 4.56M | 3.42M | 1.14M |
| Interest Expense | 345K | 420K | 483K | 307K | 90K |
| Other Income / Expenses | (226K) | 1.1M | 4.07M | 3.12M | (2.45M) |
| Income Before Tax | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Pre-Tax Margin | — | — | -475.0% | -1079.9% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Net Margin | — | — | -475.0% | -1079.9% | — |
| EPS (Basic) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| EPS (Diluted) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| Weighted Avg Shares | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
| Weighted Avg Shares (Diluted) | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.